February's FDA approvals feature advancements in cardiology, neurology, infectious diseases, and rare disorders, including the first trials for genetically modified pig kidney transplants and novel treatments for Parkinson’s disease and spinal muscular atrophy.
Mesalamine 800 mg delayed-release tablets have been launched, and FDA approval has been granted for lenalidomide, with plans for entry into the U.S. generic market in 2026.
Researchers examined systemic absorption, metabolism, and excretion of tattoo ink tracers, providing evidence for a cutaneous first-pass effect and measuring systemic exposure levels.